Yoshiyasu Aoki

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions
    Y Aoki
    Medicine Branch and HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 96:1599-601. 2000
  2. ncbi Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive 12N226, Bethesda, MD 20892 1907, USA
    Expert Rev Anti Infect Ther 2:213-25. 2004
  3. ncbi HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1907, USA
    Blood 104:810-4. 2004
  4. ncbi Targeted inhibition of angiogenic factors in AIDS-related disorders
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive 12N226 MSC1907, Bethesda, MD 20892, USA
    Curr Drug Targets Infect Disord 3:115-28. 2003
  5. ncbi Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Drug Targets Cardiovasc Haematol Disord 3:81-96. 2003
  6. ncbi Neoplastic conditions in the context of HIV-1 infection
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr HIV Res 2:343-9. 2004
  7. ncbi Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:1535-42. 2003
  8. ncbi Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus
    Y Aoki
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 98:3042-9. 2001
  9. ncbi Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas
    Y Aoki
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 41:229-37. 2001
  10. ncbi Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders
    Y Aoki
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 97:2173-6. 2001

Detail Information

Publications15

  1. ncbi Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions
    Y Aoki
    Medicine Branch and HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 96:1599-601. 2000
    ..The results of the current study suggest that these cytokines play a central role in the pathogenesis and manifestations of PEL. (Blood. 2000;96:1599-1601)..
  2. ncbi Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive 12N226, Bethesda, MD 20892 1907, USA
    Expert Rev Anti Infect Ther 2:213-25. 2004
    ..Based on advances in the understanding of Kaposi's sarcoma-associated herpesvirus-related disorders and availability of antiretroviral agents, current and future therapeutic approaches will be discussed...
  3. ncbi HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1907, USA
    Blood 104:810-4. 2004
    ..These results can explain why AIDS-KS is more frequent and clinically more aggressive than KS in other immunodeficiency states...
  4. ncbi Targeted inhibition of angiogenic factors in AIDS-related disorders
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive 12N226 MSC1907, Bethesda, MD 20892, USA
    Curr Drug Targets Infect Disord 3:115-28. 2003
    ....
  5. ncbi Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Drug Targets Cardiovasc Haematol Disord 3:81-96. 2003
    ..Deregulated cytokines may represent potential targets of novel therapeutic strategies...
  6. ncbi Neoplastic conditions in the context of HIV-1 infection
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr HIV Res 2:343-9. 2004
    ..Understanding the direct and indirect roles of HIV-1 in the pathogenesis of neoplastic conditions could provide the rationale for prevention and development of new treatments for AIDS-associated malignancies...
  7. ncbi Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:1535-42. 2003
    ..Since constitutive STAT3 activation and survivin expression have been widely documented in different types of cancers, their linkage may extend to many malignancies and be critical to their pathogenesis...
  8. ncbi Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus
    Y Aoki
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 98:3042-9. 2001
    ..These results document that vIL-6 does not bind IL-6R and suggest that conformational change may be critical to vIL-6 function...
  9. ncbi Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas
    Y Aoki
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 41:229-37. 2001
    ..Although the precise mechanisms by which VEGF/VPF can promote vascular permeability are not fully understood, VEGF/VPF stimulation of vascular leakage may be critical to the pathogenesis of PEL...
  10. ncbi Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders
    Y Aoki
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 97:2173-6. 2001
    ..Circulating vIL-6 levels were associated with HIV(+) status (P <.0001). However, within the HIV(+) cohort, serum vIL-6 levels were not associated with the occurrence of KSHV-associated malignancies (P =.43). (Blood. 2001;97:2173-2176)..
  11. ncbi Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo
    Sabrina Villalba
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Leukoc Biol 74:880-8. 2003
    ..The inactivation of circulating SDF-1 may be critical in permitting local gradients to develop and direct cell trafficking...
  12. ncbi Immunoblastic lymphoma in persons with AIDS-associated Kaposi's sarcoma: a role for Kaposi's sarcoma-associated herpesvirus
    Eric A Engels
    Viral Epidemiology Branch, Division of Cancer and Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20892, USA
    Mod Pathol 16:424-9. 2003
    ..We conclude that Kaposi's sarcoma-associated herpesvirus is present in some immunoblastic lymphomas in persons with AIDS-associated Kaposi's sarcoma...
  13. ncbi Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis
    Lei Yao
    Experimental Transplantation and Immunology Branch, CCR, National Cancer Institute, National Institutes of Health, Bldg 10, Rm 12N226, MSC 1907, Bethesda, MD 20892, USA
    Blood 102:3900-5. 2003
    ....
  14. ncbi Pathogenesis and manifestations of human herpesvirus-8-associated disorders
    Yoshiyasu Aoki
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 40:143-53. 2003
    ..This review will focus on several HHV-8 gene products that exhibit proinflammatory and proangiogenic activities or act as transcriptional activators of cellular cytokines that are involved in the pathogenesis of HHV-8-related disorders...
  15. ncbi A pilot study of cidofovir in patients with kaposi sarcoma
    Richard F Little
    HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Infect Dis 187:149-53. 2003
    ..This study does not provide proof of principle for the treatment of KS with CDV. However, it remains possible that antiherpesvirus therapy can be developed for herpes-induced tumors...